L. Parham

发表

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis

S. Yancey, M. Wechsler, B. Raby, 2020, Rheumatology International.

Lapatinib‐Induced Liver Injury Characterized by Class II HLA and Gilbert's Syndrome Genotypes

C. Dollery, C. Hunt, C. Spraggs, 2012, Clinical pharmacology and therapeutics.

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

M. Piccart, Z. Aziz, D. Fraser, 2017, The Pharmacogenomics Journal.

HLA-DRB1*07:01 biomarker characterization of hepatotoxicity during lapatinib combination therapies in ALTTO.

Z. Aziz, D. Fraser, L. Warren, 2015 .

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.

K. King, P. Goss, L. Briley, 2015, Pharmacogenomics.

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir

K. King, A. Hughes, W. Spreen, 2020, The Journal of antimicrobial chemotherapy.

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.

Daniel J Schaid, Colin F Spraggs, Lon R Cardon, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01

A. J. Slater, G. McVean, K. King, 2015, The Pharmacogenomics Journal.

A Randomized Phase 2 Study of an Anti-Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

P. Rosenfeld, R. Danis, E. Reichel, 2018, Ophthalmology. Retina.

Abstract PD10-05: HLA-DQA1*02:01/DRB1*07:01 as a biomarker for lapatinib-induced hepatotoxicity: prospective confirmation in a large randomised clinical trial (TEACH, EGF105485)

K. King, D. Schaid, S. McDonnell, 2012 .

Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib.

T. Johnson, L. Briley, A. du Bois, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.

D. Schaid, L. Cardon, S. McDonnell, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.

K. King, P. Goss, L. Briley, 2015, Pharmacogenomics.